NO20011440L - mGluR5-antagonister for behandling av smerte og angst - Google Patents

mGluR5-antagonister for behandling av smerte og angst

Info

Publication number
NO20011440L
NO20011440L NO20011440A NO20011440A NO20011440L NO 20011440 L NO20011440 L NO 20011440L NO 20011440 A NO20011440 A NO 20011440A NO 20011440 A NO20011440 A NO 20011440A NO 20011440 L NO20011440 L NO 20011440L
Authority
NO
Norway
Prior art keywords
pain
treatment
anxiety
antagonists
mglur5 antagonists
Prior art date
Application number
NO20011440A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011440D0 (no
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Original Assignee
Novartis Ag
Sibia Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011440(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis Ag, Sibia Neurosciences Inc filed Critical Novartis Ag
Publication of NO20011440D0 publication Critical patent/NO20011440D0/no
Publication of NO20011440L publication Critical patent/NO20011440L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
NO20011440A 1998-10-02 2001-03-21 mGluR5-antagonister for behandling av smerte og angst NO20011440L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
NO20011440D0 NO20011440D0 (no) 2001-03-21
NO20011440L true NO20011440L (no) 2001-05-15

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011440A NO20011440L (no) 1998-10-02 2001-03-21 mGluR5-antagonister for behandling av smerte og angst

Country Status (21)

Country Link
EP (1) EP1117403B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002526408A (cg-RX-API-DMAC7.html)
KR (1) KR20010088832A (cg-RX-API-DMAC7.html)
CN (1) CN1187048C (cg-RX-API-DMAC7.html)
AT (1) ATE255894T1 (cg-RX-API-DMAC7.html)
AU (1) AU765644B2 (cg-RX-API-DMAC7.html)
BR (1) BR9914215A (cg-RX-API-DMAC7.html)
CA (1) CA2345137A1 (cg-RX-API-DMAC7.html)
DE (1) DE69913548T2 (cg-RX-API-DMAC7.html)
DK (1) DK1117403T3 (cg-RX-API-DMAC7.html)
ES (1) ES2213389T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0200553A3 (cg-RX-API-DMAC7.html)
ID (1) ID29095A (cg-RX-API-DMAC7.html)
IL (2) IL142047A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011440L (cg-RX-API-DMAC7.html)
NZ (1) NZ510743A (cg-RX-API-DMAC7.html)
PL (1) PL202906B1 (cg-RX-API-DMAC7.html)
PT (1) PT1117403E (cg-RX-API-DMAC7.html)
RU (1) RU2232017C2 (cg-RX-API-DMAC7.html)
SK (1) SK4382001A3 (cg-RX-API-DMAC7.html)
WO (1) WO2000020001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
ATE297734T1 (de) 2000-12-22 2005-07-15 Hoffmann La Roche Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
AU2016273751B2 (en) 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
CN1321087A (zh) 2001-11-07
DE69913548D1 (de) 2004-01-22
BR9914215A (pt) 2001-07-03
SK4382001A3 (en) 2001-08-06
EP1117403B1 (en) 2003-12-10
HUP0200553A3 (en) 2002-11-28
AU6198499A (en) 2000-04-26
NZ510743A (en) 2003-10-31
KR20010088832A (ko) 2001-09-28
ES2213389T3 (es) 2004-08-16
EP1117403A1 (en) 2001-07-25
CA2345137A1 (en) 2000-04-13
JP2002526408A (ja) 2002-08-20
PL346876A1 (en) 2002-03-11
DE69913548T2 (de) 2004-09-23
IL142047A (en) 2007-09-20
IL142047A0 (en) 2002-03-10
HUP0200553A2 (hu) 2002-07-29
AU765644B2 (en) 2003-09-25
NO20011440D0 (no) 2001-03-21
ID29095A (id) 2001-07-26
PL202906B1 (pl) 2009-08-31
PT1117403E (pt) 2004-04-30
DK1117403T3 (da) 2004-04-13
RU2232017C2 (ru) 2004-07-10
WO2000020001A1 (en) 2000-04-13
CN1187048C (zh) 2005-02-02
ATE255894T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
NO20011440D0 (no) mGluR5-antagonister for behandling av smerte og angst
NO20020770D0 (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av fedme
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
EP1129089A4 (en) SPIRO-INDOLE AS Y5 RECEPTOR ANTAGONISTS
DE60233040D1 (de) Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
TR200200408T2 (tr) Yeni spiro bileşikleri
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
NO20004419D0 (no) Ny anvendelse
DE60103384D1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
ITRM990426A0 (it) Impiego di inibitori della sostanza p per il trattamento degli adenocarcinomi.
ATE358483T1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos